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1. Aim
To prepare guidelines for testing new endocrine agents for
therapy of cancer.
2. Introduction
2.1. The current situation
The endocrine agents in current use for the treatment of
cancer have principally originated from programmes aimed
at producing drugs for other indications. Observations of
their actions and side-effects in patients subsequently
resulted in their use as anti-cancer agents. Their beneficial
effects in patients with hormone-sensitive cancers have led to
the production of a large number of newer compounds,
often developed for patients with cancer. In addition, patients
with types of cancer other than the classical steroid-sensitive
cancers have been considered as candidates for endocrine-
related therapies.
2.2 The problem
Although current guidelines for the conduct of phase I and
II trials of cytotoxic agents may cover some problems of
endocrine-type therapies, these agents work in radically
different ways from cytotoxic drugs and different problems
are associated with their development. Thus, the selection
procedures are different. The dose needed to achieve a
particular maximal effect can often be determined and may
be much lower than the maximal tolerated dose (MTD).
Unlike cytotoxic agents, most currently available endocrine
therapies are best given by continual oral therapy which
contrasts markedly to the situation for cytotoxic agents,
where doses near the MTD are generally given intermittently
and intravenously.
Guidelines for phase I and II clinical trials of cytotoxic
drugs in the treatment of cancer have been agreed by the
Cancer Research Campaign Phase I/II Clinical Trials Com-
mittee, and these have been used to draw up equivalent
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recommendations for clinical trials with endocrine agents.
We recognise that the requirement of the licensing auth-
ority for physicians undertaking a limited trial of a drug in
their own patients are less demanding than those required of
a pharmaceutical company seeking a clinical trials certificate.
For the academic physician, however, the cost of such
toxicology would prevent many potentially useful anti-cancer
agents being tested. The aim of this document is, therefore,
to establish guidelines for the selection, preclinical toxico-
logy, quality control and clinical study of new endocrine
agents selected in hospitals and university departments.
3. The molecular basis of hormone action in cancer and
selection of novel agents
It is accepted that steroid hormones are modulators or
activators of cell proliferation and that most are likely to
work by modifying growth factor activity. The majority of
relevant growth factors have not yet been defined and
therefore other methods of screening need to be examined.
These are as follows.
3.1. Mammary tumours: anti-oestrogens
3.1.1. Affinity for oestrogen receptors (calf, rat and human
uterine cytosol) and comparison with affinity for other
steroid receptors.
3.1.2. Inhibition of the growth of either the transplanted,
hormone-dependent MXT-M3.2 mammary tumour of the
mouse and determination of oestrogenic side effects (uterine
weight) or the growth of the nitrosomethylurea (NMU) or
dimethylbenzanthracene (DMBA)-induced primary rat
mammary tumours.
3.1.3. Anti-oestrogenic and oestrogenic activity in the imma-
ture mouse.
3.1.4. Inhibition of growth of a hormone dependent breast
cancer cell line, e.g. MCF-7.
In all the four sections above, the effect of the drug on the
oestrous cycle should also be studied. In the case of hor-
mones linked to cytotoxic molecules, an additional set of
requirements must be studied, including reversibility of
receptor binding, the alkylating potency in the Epstein NBP-
test and comparison of inhibition of the hormone-
independent MDA-MC-or Evsa-T cell lines with a hormone
dependent cell line such as MCF-7. Additional anti-tumour
activity should be examined in further non-hormone sensitive
tumour models (e.g. P388 and the B16-melanoma and color-
ectal human xenografts). The reversibility of their inhibitory
effect on hormone sensitive tumour cell lines should also be
investigated.
3.2. Mammary tumours: enzyme inhibitors
3.2.1. ID50 of enzyme of interest and specificity of enzyme
of interest.
3.2.2. Examination of activity against enzymes in different
tissues.
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3.2.3. Examination of effects on hormone sensitive organ
weights in animals.
3.2.4. Effect on NMU or DMBA-induced mammary
carcinomas.
3.2.5. Affinity for steroid receptors.
3.2.6. Inhibition of ovarian or peripheral hormnone output
and gonadotrophin drive.
3.3. Progestin-like compounds
3.3.1. Affinity for progesterone receptor and comparison
with other receptors.
3.3.2. Anti-oestrogenic effect in normal tissues of mice and
rats.
3.3.3. Anti-progestin effects by examination of organ weights
after progesterone administration and concomitant estima-
tion of antiglucocorticoid effects.
3.3.4. Effect on NMU and DMBA mammary tumour
growth.
3.3.5. Direct antitumour effects in vitro in cell lines.
3.4. Releasing hormone agonists/antagonists
3.4.1. Effect on isolated pituitary cultures.
3.4.2. Measurements of endocrine effects in vitro and in vivo.
3.4.3. Effect on NMU and DMBA mammary tumour
growth.
3.4.4. Effect on animal model of prostatic carcinoma (see
below).
3.4.5. Effect on ovulation.
3.5. Prostatic carcinomas: antiandrogens
3.5.1. Affinity for androgen receptors and comparison with
other receptors..
3.5.2. Anti-androgenic effect in intact rats and mice.
3.5.3. Inhibition of the hormone-dependent R3327H-PC of
the rat.
3.5.4. Direct anti-androgenic effect in castrated rats and
mice.
3.5.5. Androgenic effect in immature rats and mice.
3.5.6. Inhibition of the hormone-sensitive R3327G tumour
or Noble Nb-PC of the rat.
3.5.7. Effect in the R3327-relapse PC-model.
A wider endocrinological testing than the above may be
necessary to establish selectivity of action (e.g. that an anti-
oestrogen does not also affect progestogen or androgen
dependent functions).
4. Animal models
There are many animal models of hormone-sensitive human
cancer. The most common are:
(a) For breast cancer: the DMBA and NMU-induced
mammary carcinomas, the xenografted MXT (trans-
plantable) tumour or the MCF-7 cell line implanted in
nude mice (with oestrogen pellet).
(b) For prostate cancer: the R3327 rat model seems the
best currently available.
There is no economically suitable model for post-menopausal
breast cancer, since the tumour induction rate in
ovariectomised rats is low. Oestrogen pellets implanted in
ovariectomised rats should be investigated as a possible
model for this category of patients.
All transplantable models tend to lose hormone sensitivity
unless hormone-supplemented. Thus, endocrine sensitivity
should be checked by carrying out oophorectomy in each
transplant generation if these models are used. Early passage
samples are preferable to late.
Although comparative studies have shown a moderately
good correlation between the animal and human responses
to various drugs it was accepted that difference in metabo-
lism made failure in the animal model difficult to interpret.
Thus, in the face of good receptor binding activity or
steroid-inhibitory activity, a negative animal test should not
preclude human evaluation.
5. Control recommendations for endocrine agents prepared
by academic units
These recommendations are the same for any new investiga-
tional agent. Information should be available concerning:
5.1. Purity
As documented by appropriate physiochemical, spectroscopic
and chromatographic techniques.
5.2. Sterility
As documented by a negative pyrogen test and cultures.
(Not needed for oral dosage forms.)
5.3. Stability
As documented by analysis after storage at -20°C and at
4°C for at least 6 months to a year. More information about
potential instability can be gained from short periods of
storage at higher temperatures, e.g. 1 week at 50°C. The
effect of humidity is also important with oral dosage forms.
5.4. Specificity of action
We recommend that, for enzyme inhibitors, several enzymes
in the steroid synthetic pathway from two or three sites are
examined for inhibitory activity and several hormone recep-
tors are studied for binding in the case of hormone antag-
onists. Enantiomer or geometrical isomer-selective synthesis
is preferable to unselective synthesis since enantiomers or
geometric isomers can have opposing effects or biological
activity may reside largely in one such isomer whereas side-
effects may be the same for each or even greater for the
inactive isomer.
6. Minimal toxicological data for products of hospitals and
academic units (for a limited number of patients)
6.1. General pharmacodynamic screen
A limited study in a small rodent species such as the mouse
or rat would allow an assessment of the selectivity of the
new agent in vivo and might enable the prediction of dose-
related adverse effects. This phase could follow protocols
previously published. In addition, it may be useful to use the
animals to assess the relationship between pharmacodynamic
action, dose and plasma level of the new agent. The pre-
clinical toxicology should be carried out using the material
in its final formulation.
6.2. Single dose (acute) toxicity
The purpose of this would be to identify target organs and
to suggest a ceiling for the repeat dose toxicity study. An
approximate value for the LDo10 (or LD50) should be aimed
at. Animals should be examined at 14 days after dosing or at
death (if before this). The investigation should include gross
pathology, histopathology of macroscopically abnormal
tissues, haematology and simple blood and urine chemistry.
6.3. Repeated dose study
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and one non-rodent species is desirable for any new agent.
However, if one is considering new products arising in or
selected from hospital or academic laboratories that, in the
first instance, would be investigated in a limited number of
patients over a limited period, it may be possible to modify
this to carry out a 4-week study of five times weekly or
continuous dosing in one species using the sex that is most
appropriate for the new agent (e.g. female animals for
aromatase inhibitors). The study should be conducted at two
or three dose levels in 20 rats in each group. The lower dose
ideally should be one that gives rise to plasma levels of the
new agent within the range of its effective levels and which
would be the levels most likely to be therapeutically relevant
in patients. The second dose should be in the region of the
ceiling established in the single dose study. Ideally this would
be at least 10 times the expected (therapeutic) low dose.
During treatment, food and water intake, body weight and
general behaviour/health of the animals would be deter-
mined. Any animals dying or becoming seriously adversely
affected would be given detailed examination as would the 3-
or 4-week survivors. This examination would be similar to
that indicated under the single dose study.
Animal species probably differ more widely at the endocri-
nological level than for any other biological parameter.
Thus species selection for relevance in man is more difficult
than normal. Taking a very broad view on the basis of toxi-
cological experience, the rat is the best predictor of hazard.
We would therefore recommend the rat is the species for the
single and repeated dose studies. The disadvantage is the
larger quantity of new compound required compared with
the situation where the mouse would be used. Group sizes
should be of six to ten animals. The route of administration
should be the anticipated route for man. For orally adminis-
tered agents, gavage rather than intake with the food should
be adopted. Consideration must be given to suitable control
groups. This is particularly important where the formulation
of the dose may involve suspending agents etc.
A repeated dose study of 3-4 weeks in rats should permit a
1-2 week trial in patients. This would not be long enough to
assess a new product adequately but would at least provide
ample opportunity of determining the endocrinological
changes induced in man by the new agent, any acute
symptoms and sites of toxicity, and preliminary data on the
simple pharmacokinetics and metabolism of the new com-
pound. The latter aspect should be paralleled by similar
studies in the rat.
6.4. Special considerations
The considerations above would only apply to women of
non-childbearing age and not for use in an adjuvant setting.
If a new agent is to be given to premenopausal women
extensive additional mutagenicity studies are required (e.g.
Ames test and DNA repair in hepatocytes and a study of
their teratogenic potential and effects on reproductive func-
tions in an animal model). If adjuvant is planned, much
more extensive longer term toxicity is needed.
7. Pharmacokinetics and endocrine studies incorporated into
toxicology studies
To save cost and animals, blood should be taken where
possible for endocrine and drug measurements to permit
'area under the curve' calculations. This would assist in
defining the dose and plasma concentration-response rela-
tionship for the endocrine effect.
agents we do not aim to obtain the maximum tolerated dose
(MTD).
It may be that the dose required to give the maximum
endocrine effect is near the MTD and if this is the case it is
likely that the agent will not be useful for the following
reasons:
(a) In endocrine therapy, chronic therapy is usually
required to establish and maintain the desired endocrine
effect and hence fully effective doses need to be well
below the MTD.
(b) Hormonal therapy is usually considered as an early
treatment option for patients who have a good perfor-
mance status and hence risk/benefit considerations are
different from those for cytotoxic agents.
8.1. Clinical eligibility ofpatients
In addition to the information outlined below the following
publication is recommended for more detailed consider-
ations: WHO Handbook for Reporting Results of Cancer
Treatment, WHO Offset Publication No. 48, World Health
Organization, Geneva, 1979. Obtainable from HMSO.
8.1.1. Physician responsible. Each patient should be in the
care of a cancer physician experienced in management of the
relevant tumour type and familiar with investigation of new
drugs and management of drug toxicity. Ideally such
physicians should also possess some specialist knowledge of
endocrinology.
8.1.2. Original diagnosis. Microscopically confirmed diag-
nosis of either locally advanced or metastatic cancer.
8.1.3. Disease status. Disease progression despite accepted
first-line endocrine therapy. Patients with breast cancer
should have oestrogen receptor positive or unknown status.
8.1.4. Predicted survival. A predicted survival of not less
than 4 months.
8.1.5. Treament status. At least a 3-week interval since the
last dose of therapy and recovery from reversible toxicity. At
least a 6-week interval since the predicted completion of
release from the last depot preparation.
It is important to establish that the endocrine effects
induced by the previous endocrine treatment are no longer
present.
8.1.6. Haematological requirements. Minimal haemato-
logical requirements: WBC >3,000mm-3; platelets
> 100,000mm- 3 (excluding patients with acute leukaemia).
8.1.7. Biochemical status. Minimal biochemical parameters:
normal values for organs related to drug metabolism and
excretion or related to major toxic manifestations. Devi-
ations up to 25% above the upper limit of normal liver
function will be acceptable however.
8.1.8. Consent. No patient will be entered into the study
without his or her consent or that of a parent or guardian
for those under 16 years, following a full explanation of the
purpose and limited expectations of the study.
8.1.9. Menopausal status. For females, menopausal status
should be checked by measuring gonadotrophin levels if in
doubt.
8.1.10. Contraindications. Women who are thought to be
pregnant or breast feeding. Massive visceral involvement.
8. The clinical trial Other endocrine illness.
In general the aim of the first clinical studies is to determine
the minimum dose of the agent needed to lead to the
maximum endocrine effect. Unlike the case for cytotoxic
8.1.11. Other considerations. (a) The marked diurnal
rhythm of endogenous endocrine parameters should be taken
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may also be evaluated in patients with endometrial cancer,
with the provision that anti-oestrogens have not, to date,
been found to be effective in endometrial cancer.
9. Dosing shed
9.1. Calculation of the starting dosefor new endocrine agents
For most new endocrine agents the safe starting dose will be
1/10 of the LD1o in mouse expressed as mgm-2. Pharma-
cokinetic measurements should be used to adjust the
therapeutic dose to that which gives a blood level equiva-
lent to that which is effective in the animal species.
To calculate the approximate amount of drug for the
initial phase I study, the LD50 is multiplied by 103, e.g. if
the LDso is 200mgkg-1, the amount needed to carry out
the phase I study is approximately 200g.
9.2. Escalation
9.2.1. Single dosing. The classical or modified Fibonacci
escalation is not appropriate for these agents. Escalation
must depend on obtaining accurate endocrine and drug
measurement data after each dose level. In general, however,
we recommend a 25% dose escalation with a minimum of
five patients at each dose level, each of whom should receive
only a single dose of the investigational agent.
9.2.2. Repeat dosing. Once an endocrine response is seen,
repeat dosing for a maximum of 7 days at one-half to one-
third of this dose can be carried out in a further selection of
4-6 patients at each dose level. Endocrine and drug measure-
ment studies should be done before, during and after this
therapy and no further therapy given for 3 weeks after this
week's treatent.
If no endocrine effect is observed after a single dose, the
level of the repeat dose will depend on the pharmacokinetics.
9.2.3. Continued treatment. It was recognised that, in the
event of a patient responding to therapy, it would be
unethical not to allow these patients to continue with
treatment, assuming careful monitoring for side effects.
9.2.4. Dose modification. Any adverse effect such as elec-
trolyte disturbance or hypoadrenalism are grounds for termi-
nating the study. In testing anti-oestrogens or progestins, any
signs of thromboembolism are grounds for terminating the
study.
10. Serial observations
Appendices 1, 2 and 3 and 4 summarize minimum standard
investigations.
10.1 Endocrine effects
Some of the measurable endocrine effects in humans which
may act as indicators of effectiveness for the various agents
are as follows (provided that the agent does not cross-react
with the analysis for circulating compound):
10.1.1. Anti-oestrogens - SHBG, LH, FSH, oestradiol, pro-
gesterone, vaginal smears.
10.1.2. Aromatase inhibitors - oestradiol, oestrone, oestrone
sulphate, testosterone, cortisol. Depending on sex and men-
strual status, LH and FSH may be worthwhile.
10.1.3. LHRH analogues - LH, FSH, oestradiol,
testosterone.
10.1.4. Anti-androgens - 5-alpha dihydrotestosterone, testo-
sterone, LH, FSH.
10.1.5. Anti-prolactins - prolactin.
10.1.6. Progestogens- LH, FSH, SHBG, cortisol, oestradiol,
oestrone, progesterone.
10.1.7. Anti-progestins- LH, FSH. cortisol, oestradiol,
progesterone.
The marked diurnal rhythm of endocrine parameters
should be taken into account. Clinical observations of effects
on reproductive function may be appropriate in addition to
endocrine monitoring.
11. Recording of toxicity and response
Appendices 3 and 4 give guidelines to be used in addition to
history, examination and any other relevant investigation.
12. Supportive therapy
Full supportive care and treatment will be given to each
patient (antibiotics, transfusions, diet, etc.). Hospitalisation
should be recommended for agents with unpredictable
toxicity.
12.1. Additional chemotherapy
Administration of other antineoplastic or endocrine agents
during the study period disqualifies the patient from the
study.
12.2. Other concurrent therap)
A record of all concurrent non-anti-tumour drugs used
should be provided at the end of the study.
13. Flow of information and recolds
13.1. Stud) co-ordinator
A co-ordinator will be appointed to collate all studies on a
single drug within a group.
13.2. Registration
Qualifying patients are registered with the study co-ordinator
for assignment of drug dose and starting date.
13.3. Toxicity grading
See Appendix 3.
14. Tumour response
See Appendix 4.
15. Flow sheets
Flow sheets including tumour measurements will be used to
record day to day observations on symptoms, signs and
laboratory data.
16. Sunmary sheet
A summary sheet will be prepared by the study co-ordinator.
17. Sudden toxicity procedure
The study coordinator is called at once in case of pro-
nounced toxicity; he or she will inform the investigators in
charge of other patients in the study.OPERATION MANUAL 269
18. Regulatory requirements
A form for doctors and dentists exemption certificates must
be submitted to the DHSS (form MLA 162) (UK only).
Appendix 1
Day
End of
Onset 1 2 Weekly study
Urine casts X X
Peak flow X XX X X
ECG X After7days X
Chest X-ray X After7days X
Clinical history and examination X X X
Appendix 2
WHO performance scale
Scale performance
0 Able to carry out nomal activity without restriction.
1 Restricted in physically strenuous activity but ambula-
tory and able to carry out light work.
2 Ambulatory and capable of all self-care but unable to
carry out any work; up and about more than 50% of
waking hours.
3 Capable of only limited self-care; confined to bed or
chair more than 50% of waking hours.
4 Completely disabled; cannot carry on any self-care;
totally confined to bed or chair.
Appendix 3
Definitions of toxicity
Toxicity: Always related to a given dose schedule at a given
dose level for a given duration of time.
Grade 0 Non-toxic dose: a dose which causes no recognis-
able effects whatsoever.
Grade 1 Subtoxic dose: a dose which causes consistent
changes of haematological or biochemical or other
parameters and might thus herald toxicity at the
next higher dose level or with prolonged drug
administration.
Grade 2 Minimal toxic dose: the smallest dose at which
one or more patients show consistent, readily
reversible drug toxicity.
Grade 3 The dose which causes moderate reversible toxi-
city in the majority of patients.
Grade 4 Maximally tolerated dose: the highest tolerable,
safe dosage.
Appendix 4
Tumour masses are counted and measured at regular inter-
vals. Measurable tumour masses are defined as the product
of the longest x the widest perpendicular diameter. The third
dimension can be added, where possible. Measurability is
arbitrarily defined as reproducibility of simultaneous
measurements within 50% by independent observers.
1. Complete tumour regression is defined as complete disap-
pearance of all recognisable tumour masses and/or bio-
chemical changes directly related to the tumour.
2. Complete remission is defined as complete tumour
regression (1) and complete disappearance of indirect
(host mediated) symptoms, signs, haematological and
biochemical parameters.
3. Partial regression is defined as >50% decrease of one or
more tumour lesions in the absence of progression or
occurrence of new lesions elsewhere.
4. Improvement applies only to well-outlined palpable
lesions, and is defined as >25 to <50% regression in the
absence of progression or occurrence of new lesions
elsewhere.
5. Stable disease: changes smaller than those outlined under
(3), (4) and (6).
6. Progressive disease: occurrence of any new lesion or
increase of well outlined new lesion by 33%.